Overall volumes in futures & options currently stand at 1.31 crore contracts with a turnover of Rs. 8,82,993.97 crore.

Overall volumes in futures & options currently stand at 1.31 crore contracts with a turnover of Rs. 8,82,993.97 crore.

In the coming session, the level of 11,490 is likely to act as an immediate resistance level, followed by 11,545, while on the downside, 11,360 is likely to act as an immediate support level, followed by 11,300. Stocks in news: IRB Infrastructure Developers, Vodafone Idea, Lupin, Cadila Healthcare, DHFL, Indo Amines, Bandhan Bank, Karnataka Bank and Lumax Auto Technologies.

Indian equity benchmarks, after registering their best week since November, look set to continuing their jubilant run at the start of the week as global cues are supportive and Asian markets are mostly trading higher. At the time of writing, the SGX Nifty was trading with gain of 23 points at 11,497.

Many of you are interested to know what the fund managers are buying and selling. So, let’s find out which stocks attracted the fund manager most in the month of February 2019.

The stocks that are likely to witness significant movement on the bourses on March 18 are Voltas, Natco Pharma, Aarti Drugs, Wipro and Religare Enterprises.

Come March, everyone checks out for one last time, whether their tax-saving investments for the financial year is in order. Some even try to make last-minute investments in the last week of March. Here is a list of steps to go through before making hurried investments. 

FMCG stocks on Friday showed a negative trend despite benchmark index touching fresh highs for the year 2019. The sector took cues from HUL which hinted on lower volumes growth for the fourth quarter of FY19.

Aarti Drugs announced that its board approved buyback of around 1.2 per cent equity shares. The buyback price is set at Rs. 900 per share, which is a 37 per cent premium to its, Friday, 15 March closing.

Glenmark Pharmaceuticals received ANDA approval for Clindamycin and Benzoyl Peroxide Gel. The United States Food and Drug Administration (USFDA) gave Glenmark the final approval for Clindamycin and Benzoyl Peroxide Gel, a generic version of BenzaClin Gel of Valeant Bermuda.